- Product NameCarbaglu
- Brief DescriptionInhibitors
- Purification99.00%
- Biological ActivityCarglumic acid is an orphan drug used for the treatment of hyperammonaemia in patients with N-acetylglutamate synthase deficiency. This rare genetic disorder results in elevated blood levels of ammonia, which can eventually cross the blood-brain barrier and cause neurologic problems, cerebral edema, coma, and death. Carglumic acid was approved by the U.S. Food and Drug Administration (FDA) on 18 March 2010.
- Target NameOthers
- CAS No. 1188-38-1
- Calculated MW 190.15
- Formulation C6H10N2O5
- Storage 3 years -20˚C powder;2 years -80˚C in solvent;
